Top DoD pharmaceutical preparation manufacturing contractors
In the 12 months ending Oct 5, 2026, the Department of Defense obligated $64.7M in net prime contract dollars under NAICS 325412, down 23.6% from $84.6M in the preceding 12 months. 79 prime contractors received positive obligations, and 5 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Defense. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
DoD publishes contract data to USAspending with a 90-day delay, so the most recent months understate DoD activity.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top DoD contractors for NAICS 325412
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceuticals USA, Inc. | $31.0M | $40.2M | 45.6% | — |
| 2 | Canadian Commercial Corporation | $14.4M | $11.1M | 21.2% | — |
| 3 | Novartis Pharmaceuticals Corporation | $4.5M | $426K | 6.6% | ▲ 21 |
| 4 | Cardinal Health 414, LLC | $3.6M | $3.6M | 5.3% | ▲ 1 |
| 5 | Cardinal Health, Inc. | $1.4M | $1.5M | 2.1% | ▲ 2 |
| 6 | Jubilant Hollisterstier LLC | $1.2M | $1.0M | 1.7% | ▲ 6 |
| 7 | Lantheus Medical Imaging, Inc. | $1.1M | $676K | 1.6% | ▲ 9 |
| 8 | Genentech USA, Inc | $940K | $959K | 1.4% | ▲ 5 |
| 9 | Bracco Diagnostics Inc. | $883K | $432K | 1.3% | ▲ 13 |
| 10 | Boston Scientific Corp | $842K | $1.4M | 1.2% | ▼ 2 |
| 11 | Sofie Co. | $776K | $1.2M | 1.1% | ▼ 1 |
| 12 | Petnet Solutions, Inc. | $759K | $876K | 1.1% | ▲ 2 |
| 13 | Hamamatsu/Queen's PET Imaging Center, LLC | $593K | $388K | 0.9% | ▲ 12 |
| 14 | American National Services LLC | $531K | $429K | 0.8% | ▲ 9 |
| 15 | INO Therapeutics LLC | $502K | $660K | 0.7% | ▲ 2 |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Novartis Pharmaceuticals Corporation$426K → $4.5M (+$4.0M) · now #3
- Canadian Commercial Corporation$11.1M → $14.4M (+$3.3M) · now #2
- Bracco Diagnostics Inc.$432K → $883K (+$451K) · now #9
Largest declines
- Teva Pharmaceuticals USA, Inc.$40.2M → $31.0M (−$9.2M) · now #1
- DMS Pharmaceutical Group Inc$4.3M → −$299K (−$4.6M) · no latest-period obligations
- Meridian Medical Technologies, LLC$1.2M → −$3.1M (−$4.3M) · no latest-period obligations
New to this market
12 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| Value Drug, Limited | Nov 26, 2025 | $236K |
| TRI-Pharma, Inc. | Jun 15, 2026 | $168K |
| Jubilant Draximage Radiopharmacies, Inc. | Jan 30, 2026 | $157K |
| Southeast Apothecary, Inc. | Dec 17, 2025 | $105K |
| Bhpe LLC | Jan 28, 2026 | $95K |
| Lovell Government Services Inc. | Jan 8, 2026 | $40K |
| Parata Systems LLC | Jan 14, 2026 | $39K |
| Crown Pharmaceuticals Inc | Apr 2, 2026 | $25K |
Where the money comes from
Funding sub-agencies within the Department of Defense, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| Defense Logistics Agency | $45.5M | $64.0M | Down $18.5M (28.9%) |
| Defense Health Agency | $18.9M | $13.8M | Up $5.1M (37.3%) |
| Department of the Army | $282K | $6.1M | Down $5.8M (95.4%) |
| Department of the Navy | $1K | $0 | New |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| W91YTZ23P0137 | Jubilant Hollisterstier LLC VENOM IMMUNOTHERAPY SUPPLIES (BASE) | $3.1M | Sep 30, 2027 |
Common questions
Who are the top DoD contractors for NAICS 325412?
In the latest 12 months, Teva Pharmaceuticals USA, Inc. ($31.0M), Canadian Commercial Corporation ($14.4M), Novartis Pharmaceuticals Corporation ($4.5M) received the most DoD obligations for pharmaceutical preparation manufacturing.
How concentrated is this market?
The eight largest primes held 85.4% of positive obligations, and Teva Pharmaceuticals USA, Inc. alone held 45.6%. 12 contractors won their first obligations in this market during the latest 12 months.
Are any large DoD NAICS 325412 contracts ending soon?
1 of the largest awards in this market reach their current end date in the next 18 months. The first is W91YTZ23P0137 (Jubilant Hollisterstier LLC, $3.1M obligated), ending Sep 30, 2027. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 325412 across all agencies
VA · NAICS 325412
$11.1BHHS · NAICS 325412
$777.8MDOJ · NAICS 325412
$200.6MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.